Amgen presents late-breaking Phase 2 olpasiran data at ESC 2023

Amgen today announced data from the final analysis of the Phase 2 OCEAN(a)-DOSE study of olpasiran, a small interfering RNA (siRNA) during the Late-Breaking Science Session at the European Society of Cardiology (ESC) Annual Meeting being held in Amsterdam. In the off-treatment extension period, olpasiran showed a lasting effect on Lp(a) reduction nearly a year after the last dose.

Medtronic wins approval to sell renal denervation device in China

Dive Brief: Medtronic said Monday it has received the first approval for a renal denervation system from China’s National Medical Products Administration (NMPA). The approval

May 7, 2024

Scientists identify over 5,000 genetic variants that enable certain cancers to thrive

Researchers performed saturation genome editing of the BAP1, whose dysfunction is related to cancer and impaired neurodevelopment.

July 10, 2024

Doxy.me Appoints Dr. Esteban López as Chief Medical Officer

Dr. Esteban López, Chief Medical Officer at Doxy.me What You Should Know: – Doxy.me, a telehealth platform dedicated to making telemedicine accessible to all, announced

February 8, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.